New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

What it owns vs. what it owes End of fiscal 2025, Dec 31, 2025

Debt has risen from $3.4M to $30.3M since FY19. Shareholders’ equity is 65.3% of the balance sheet. What is a balance sheet?

Dec 31, 2025 · total $32.1M

Owns

$535.0KLong-term assets
$727.0KOther short-term assets
$30.8MCash & short-term investments

Funded by

$20.9MShareholders’ equity
$11.1MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 65.3%.

Net cash fell from 65% of assets to 4% since FY19.

Total assetsNet debt (debt less cash)Net debt ÷ assets (right axis)
Assets and net debt, five years
FY19FY20FY21FY22FY24
Total assets$233M$271M$247M$182M$35M
Net debt (debt less cash)−$152M−$177M−$165M−$144M−$1.4M
Net debt ÷ assets (right axis)−65.1%−65.4%−66.8%−79.0%−3.8%
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
58.98 92.57 161.74 155.01 180.93 167.04 145.81 101.17 31.61 30.81
Receivables
0.94 0.85 1.59 1.79 2.06 1.15 4.45 4.02 4.50 —
Inventory
— — — — — 2.58 2.38 2.82 0.90 —
Total current assets
61.45 95.06 168.14 165.66 195.07 173.29 168.91 116.16 31.69 31.54
Property, Plant, Equpment (Net)
1.61 1.18 0.88 0.70 0.84 0.63 0.43 3.32 0.08 0.05
Long-Term Investments
0.77 0.77 21.40 63.16 70.57 69.75 11.35 — — —
Goodwill and Intangible Assets (Total)
— — — — — — — — 0.39 0.32
Long-term assets (Other)
0.77 0.77 0.41 0.41 0.41 0.41 — 1.50 0.02 0.02
Total non-current assets
2.38 1.95 22.68 67.30 76.09 73.77 13.33 9.69 3.51 0.54
Total Assets
63.83 97.00 190.82 232.96 271.16 247.06 182.24 125.84 35.20 32.07
Accounts Payable
4.74 3.83 4.37 9.10 4.89 5.63 9.60 — 2.19 3.22
Accrued Expenses
11.53 8.51 13.62 19.67 16.88 15.86 21.54 25.59 8.08 7.71
Current Revenue (Deferred)
— — 26.83 22.26 — — — — — —
Total current liabilities
11.53 8.51 40.45 42.89 18.48 17.62 23.46 25.59 10.37 11.04
Long Term Debt (Total)
— — — 3.35 3.67 1.92 — — 30.26 —
Non-current Revenue (Deferred)
— — 15.18 — — — — — — —
Preferred Shares of Subsidiary (Mandatory, Redeemable)
— — — — — — — — 85.50 —
Non-current Liabilities (Other)
1.57 1.72 1.56 0.00 0.00 — — 37.08 44.45 —
Total non-current liabilities
1.57 1.72 16.75 3.35 3.67 1.92 — 43.17 115.96 0.09
Total liabilities
13.10 10.22 57.19 46.25 22.16 19.53 23.46 68.76 126.33 11.13
Additional Paid In Capital
212.87 307.16 428.06 587.22 641.20 708.59 726.63 742.09 1.10 131.38
Common Stock (Net)
0.03 0.03 0.04 0.05 0.05 0.05 0.05 0.01 0.00 0.01
Retained Earnings
(162.17) (220.34) (294.35) (400.73) (392.32) (480.76) (566.23) (684.74) (92.24) (110.45)
Common Equity (Total)
50.73 86.78 133.63 186.71 249.00 227.52 158.78 57.09 (91.13) 20.95
Shareholders Equity (Total)
50.73 86.78 133.63 186.71 249.00 227.52 158.78 57.09 (91.13) 20.95
Shareholders Equity and Liabilities (Total)
63.83 97.00 190.82 232.96 271.16 247.06 182.24 125.84 35.20 32.07
Shares (Common)
0.76 0.91 1.10 1.30 1.38 1.48 1.49 1.51 2.58 9.38
Shares (Preferred)
— — — — — — — — 3.96 —
Shareholders Equity (Tangible)
50.73 86.78 133.63 186.71 249.00 227.52 158.78 57.09 (91.52) 20.62
Net Debt
(58.98) (92.57) (161.74) (151.65) (177.25) (165.12) (145.81) (101.17) (1.35) (30.81)
Total Debt
— — — 3.35 3.67 1.92 1.92 — 30.26 —

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 17, 2026